August 22, 2014 4:09 PM ET

Healthcare Equipment and Supplies

Company Overview of Veracyte, Inc.

Company Overview

Veracyte, Inc. operates as a diagnostics company in the field of molecular cytology to enhance patient outcomes and lower healthcare costs. It provides Afirma Thyroid FNA Analysis, a solution that consists of its Gene Expression Classifier, which helps physicians in reducing unnecessary diagnostic surgeries for patients with thyroid nodules. The company is also developing Afirma Malignancy Classifiers for rare forms of thyroid cancer or metastases to the thyroid that is intended to inform surgical strategy; and idiopathic pulmonary fibrosis and nodules suspicious products for lung cancer. It serves endocrinologists, radiologists, and head and neck specialists. The company was formerly known ...

7000 Shoreline Court

Suite 250

South San Francisco, CA 94080

United States

Founded in 2006

115 Employees

Phone:

650-243-6300

Fax:

650-243-6301

Key Executives for Veracyte, Inc.

Co-Founder
Age: 56
Total Annual Compensation: $380.0K
Chief Financial Officer
Age: 54
Total Annual Compensation: $201.0K
Chief Commercial Officer
Age: 45
Total Annual Compensation: $316.3K
Compensation as of Fiscal Year 2013.

Veracyte, Inc. Key Developments

Veracyte, Inc. Reports Unaudited Financial Results for the Second Quarter and Six Months Ended June 30, 2014; Reiterates Revenue Guidance for the Year 2014

Veracyte, Inc. reported unaudited financial results for the second quarter and six months ended June 30, 2014. For the second quarter, the company’s revenue was $8.7 million, an increase of 71%, compared to $5.1 million for the second quarter of 2013. Net loss and comprehensive loss was $6.7 million, or $0.31 per common share, compared with a net loss of $6.5 million, or $7.53 per common share, for the comparable period in 2013. Loss from operations was $6.561 million against $5.417 million a year ago. For the six months, the company's revenue was $16.2 million, compared to $9.5 million for the same period in 2013, also an increase of 71%. Loss from operations was $13.136 million against $11.310 million a year ago. Net loss and comprehensive loss was $13.329 million, or $0.63 per basic and diluted share, compared with a net loss of $13.385 million, or $16.47 per basic and diluted share, for the comparable period in 2013. The company reiterates its 2014 revenue guidance of $38 million to $43 million.

Veracyte, Inc. to Report Q2, 2014 Results on Aug 13, 2014

Veracyte, Inc. announced that they will report Q2, 2014 results After-Market on Aug 13, 2014

Veracyte, Inc., Q2 2014 Earnings Call, Aug 13, 2014

Veracyte, Inc., Q2 2014 Earnings Call, Aug 13, 2014

Similar Private Companies By Industry

Company Name Region
Somna Therapeutics LLC United States
The Wirebenders United States
New Star Lasers, Inc. United States
Omnitech Systems, Inc. United States
Empi, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Veracyte, Inc., please visit www.veracyte.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.